Journal of Experimental Medicine, Vol 174, 1451-1460, Copyright © 1991 by Rockefeller University Press

ARTICLES

Mapping of the C3b-binding site of CR1 and construction of a (CR1)2- F(ab')2 chimeric complement inhibitor

KR Kalli, PH Hsu, TJ Bartow, JM Ahearn, AK Matsumoto, LB Klickstein and DT Fearon
Graduate Program in Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

CR1/CR2 chimeric receptors in which various short consensus repeats (SCRs) of CR1 were attached to CR2 were transiently expressed on COS cells, and assessed for the binding of polymerized C3b (pC3b) and anti- CR2 by immunofluorescence. Of COS cells expressing chimeras containing SCR 1-4, 1-3, 2-4, 1-2, and 2-3 of the long homologous repeats (LHRs) - B or -C, 96%, 66%, 23%, 0%, and 0%, respectively, bound pC3b. K562 cells were stably transfected with wild-type CR1, deletion mutants of CR1, and the CR1/CR2 chimeras, respectively, and assayed for binding of 125I-pC3b. The dissociation constants (Kd) for pC3b of wild-type CR1 and the LHR-BD and -CD constructs were in the range of 1.0-2.7 nM, and of the CR1/CR2 chimeras containing SCRs 1-4, 1-3, and 2-4 of LHR-B or - C were 1.8-2.4, 6-9, and 22-36 nM, respectively. The factor I-cofactor function of the CR1/CR2 chimeras paralleled the C3b-binding function of the constructs. A CR1/immunoglobulin (Ig) chimeric protein was prepared by fusing SCRs 1-4 of LHR-B to the heavy chains of a murine F(ab')2 anti-nitrophenacetyl (NP) monoclonal antibody. The (CR1)2-F(ab')2 chimera, which retained its specificity for NP, was as effective as soluble, full-length CR1 in binding pC3b, serving as a cofactor for factor I-mediated cleavage of C3b, and inhibiting activation of the alternative pathway, indicating that the bivalent expression of these SCRs reconstitutes the alternative pathway inhibitory function of CR1. The feasibility of creating CR1/Ig chimeras makes possible a new strategy of targeting complement inhibition by the use of Ig fusion partners having particular antigenic specificities.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Kraus, D. M., Elliott, G. S., Chute, H., Horan, T., Pfenninger, K. H., Sanford, S. D., Foster, S., Scully, S., Welcher, A. A., Holers, V. M. (2006). CSMD1 Is a Novel Multiple Domain Complement-Regulatory Protein Highly Expressed in the Central Nervous System and Epithelial Tissues. J. Immunol. 176: 4419-4430 [Abstract] [Full Text]  
• Clemenza, L., Isenman, D. E. (2004). The C4A and C4B Isotypic Forms of Human Complement Fragment C4b Have the Same Intrinsic Affinity for Complement Receptor 1 (CR1/CD35). J. Immunol. 172: 1670-1680 [Abstract] [Full Text]  
• Yazdanbakhsh, K., Kang, S., Tamasauskas, D., Sung, D., Scaradavou, A. (2003). Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy. Blood 101: 5046-5052 [Abstract] [Full Text]  
• Rosengard, A. M., Liu, Y., Nie, Z., Jimenez, R. (2002). From the Cover: Variola virus immune evasion design: Expression of a highly efficient inhibitor of human complement. Proc. Natl. Acad. Sci. USA 99: 8808-8813 [Abstract] [Full Text]  
• Rowe, J. A., Rogerson, S. J., Raza, A., Moulds, J. M., Kazatchkine, M. D., Marsh, K., Newbold, C. I., Atkinson, J. P., Miller, L. H. (2000). Mapping of the Region of Complement Receptor (CR) 1 Required for Plasmodium falciparum Rosetting and Demonstration of the Importance of CR1 in Rosetting in Field Isolates. J. Immunol. 165: 6341-6346 [Abstract] [Full Text]  
• Nicoll, G., Ni, J., Liu, D., Klenerman, P., Munday, J., Dubock, S., Mattei, M.-G., Crocker, P. R. (1999). Identification and Characterization of a Novel Siglec, Siglec-7, Expressed by Human Natural Killer Cells and Monocytes. J. Biol. Chem. 274: 34089-34095 [Abstract] [Full Text]  
• Xiang, L., Rundles, J. R., Hamilton, D. R., Wilson, J. G. (1999). Quantitative Alleles of CR1: Coding Sequence Analysis and Comparison of Haplotypes in Two Ethnic Groups. J. Immunol. 163: 4939-4945 [Abstract] [Full Text]  
• Tas, S. W., Klickstein, L. B., Barbashov, S. F., Nicholson-Weller, A. (1999). C1q and C4b Bind Simultaneously to CR1 and Additively Support Erythrocyte Adhesion. J. Immunol. 163: 5056-5063 [Abstract] [Full Text]  
• Krych-Goldberg, M., Hauhart, R. E., Subramanian, V. B., Yurcisin, B. M. II, Crimmins, D. L., Hourcade, D. E., Atkinson, J. P. (1999). Decay Accelerating Activity of Complement Receptor Type 1 (CD35). TWO ACTIVE SITES ARE REQUIRED FOR DISSOCIATING C5 CONVERTASES. J. Biol. Chem. 274: 31160-31168 [Abstract] [Full Text]  
• Oran, A. E., Isenman, D. E. (1999). Identification of Residues within the 727-767 Segment of Human Complement Component C3 Important for Its Interaction with Factor H and with Complement Receptor 1 (CR1, CD35). J. Biol. Chem. 274: 5120-5130 [Abstract] [Full Text]  
• Quigg, R. J., Kozono, Y., Berthiaume, D., Lim, A., Salant, D. J., Weinfeld, A., Griffin, P., Kremmer, E., Holers, V. M. (1998). Blockade of Antibody-Induced Glomerulonephritis with Crry-Ig, a Soluble Murine Complement Inhibitor. J. Immunol. 160: 4553-4560 [Abstract] [Full Text]  
• Krych, M., Hauhart, R., Atkinson, J. P. (1998). Structure-Function Analysis of the Active Sites of Complement Receptor Type 1. J. Biol. Chem. 273: 8623-8629 [Abstract] [Full Text]  
• Blackmore, T. K., Hellwage, J., Sadlon, T. A., Higgs, N., Zipfel, P. F., Ward, H. M., Gordon, D. L. (1998). Identification of the Second Heparin-Binding Domain in Human Complement Factor H. J. Immunol. 160: 3342-3348 [Abstract] [Full Text]  
• Makrides, S. C. (1998). Therapeutic Inhibition of the Complement System. Pharmacol. Rev. 50: 59-88 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS